GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Glaukos Corporation
Glaukos is a company that produces innovative medical devices for the treatment of glaucoma. Its stock price reflects the success of its minimally invasive technologies. The chart tells the story of medical innovation and the struggle for reimbursement from insurance companies.
Share prices of companies in the market segment - Pharma eyes
Glaukos is an ophthalmology company offering innovative devices for the treatment of glaucoma and other eye diseases. We classify it as a Pharmaceutical Eyes company, and the chart below shows the dynamics of this segment as a whole, reflecting trends in the medical industry.
Broad Market Index - GURU.Markets
Glaukos Corporation is an ophthalmology company pioneering microinvasive glaucoma surgery. As an innovator in its niche, Glaukos is included in our GURU.Markets index. The chart below shows the overall market trend. Compare it with the company's performance to assess the state of the sector.
Change in the price of a company, segment, and market as a whole per day
GKOS - Daily change in the company's share price Glaukos Corporation
The daily price change of Glaukos Corporation (GKOS), a manufacturer of ophthalmological medical devices, reflects sensitivity to regulatory approvals, healthcare costs, and competition. GKOS's volatility is a measure of its exposure to the medical sector. GKOS's Change_Co is important for formula analysis in the pharmaceutical sector.
Daily change in the price of a set of shares in a market segment - Pharma eyes
Glaukos Corporation is a company specializing in glaucoma treatment. This chart highlights the high volatility of the MedTech sector. Comparing this to GKOS's performance helps assess how sensitive its innovative, yet niche, products are to competition and healthcare pricing.
Daily change in the price of a broad market stock, index - GURU.Markets
Glaukos is an innovative ophthalmology company developing devices for glaucoma treatment. The medical technology market is growing rapidly. The chart below shows the volatility in this sector, helping to assess how Glaukos shares respond to innovation and competition.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Glaukos Corporation
Glaukos is a manufacturer of innovative devices for glaucoma treatment. Its year-over-year performance reflects rapid growth and the adoption of its technologies in clinical practice. The chart below tells the story of this medical technology leader changing approaches to treatment.
Annual dynamics of market capitalization of the market segment - Pharma eyes
Glaukos Corporation is an ophthalmology company specializing in the development of innovative devices for the treatment of glaucoma. Its breakthrough technologies are changing approaches to treatment. This chart shows how its scientific developments, competition, and reimbursement system influence its performance in the sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Glaukos, developing innovative glaucoma treatments, is a growth story in the medical technology sector. Its stock performance is driven by the speed of adoption of its products by surgeons and the insurance system, not by the state of the economy. The chart reflects the potential of this breakthrough technology in the vast ophthalmology market.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Glaukos Corporation
Glaukos, a company developing devices and medications for the treatment of glaucoma and other eye diseases. The monthly fluctuations on the chart reflect clinical trial data, regulatory decisions, and the pace of adoption of its innovative treatments in ophthalmological practice.
Monthly dynamics of market capitalization of the market segment - Pharma eyes
This chart illustrates the dynamics of the medical technology sector, particularly in ophthalmology. For Glaukos, a pioneer in glaucoma treatment, this provides context. Its movements reflect demand for its innovative devices and its efforts to expand its product portfolio.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Glaukos is a company specializing in the development and commercialization of minimally invasive devices for the treatment of glaucoma. This is a rapidly growing segment of ophthalmology. The overall market dynamics chart allows us to assess how strong its own growth trend, driven by the implementation of its technology, allows Glaukos shares to move independently of overall market sentiment.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Glaukos Corporation
Glaukos Corporation develops innovative treatments for glaucoma. The weekly price action of this medical technology company is highly volatile and depends on clinical trial results, regulatory decisions, and changes in the reimbursement system. The chart reflects the high risks and potential of breakthrough medical technologies.
Weekly dynamics of market capitalization of the market segment - Pharma eyes
Glaukos, like the entire innovative medical technology sector, is responding to industry-wide news regarding reimbursement systems and regulatory changes. The chart below shows how the company is positioned in the context of these sectoral risks and opportunities.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Glaukos Corporation develops devices for the treatment of glaucoma. As a healthcare company, it should be less dependent on the economy. The chart will show how insulated its shares are from market fluctuations, moving in sync with product news and regulatory decisions.
Market capitalization of the company, segment and market as a whole
GKOS - Market capitalization of the company Glaukos Corporation
The Glaukos Corporation chart tells the story of innovation in the treatment of eye diseases, particularly glaucoma. Its market capitalization reflects investor confidence in its portfolio of minimally invasive surgical devices. Its dynamics show how the market values new ophthalmological technologies.
GKOS - Share of the company's market capitalization Glaukos Corporation within the market segment - Pharma eyes
Glaukos Corporation is a pioneer in microinvasive glaucoma surgery (MIGS). Its market share in the ophthalmology sector reflects its innovation and leadership in this rapidly growing niche. The chart below shows how the adoption of its technologies in clinical practice and the expansion of its product line impact its market share.
Market capitalization of the market segment - Pharma eyes
Glaukos Corporation is a pioneer in the field of microinvasive glaucoma surgery (MIGS). How big is this arena of ophthalmic innovation? The graph below shows the overall market capitalization of the sector. Its growth reflects the need for new, more gentle treatments for one of the most common eye diseases.
Market capitalization of all companies included in a broad market index - GURU.Markets
The Glaukos chart shows how the market values innovations in eye treatment. The market capitalization of this company, a pioneer in microinvasive glaucoma surgery, reflects its struggle for market share and product portfolio expansion. This diagram illustrates how a single breakthrough technology can create an entire company and then face competition.
Book value capitalization of the company, segment and market as a whole
GKOS - Book value capitalization of the company Glaukos Corporation
The book value of Glaukos Corporation, a developer of glaucoma treatment devices, reflects its tangible assets: production lines for micro-stents and R&D laboratories. The chart below shows how the company has grown its high-tech production and research capital.
GKOS - Share of the company's book capitalization Glaukos Corporation within the market segment - Pharma eyes
Glaukos Corporation is a pioneer in glaucoma treatment, and its strength lies in its high-tech manufacturing facilities. These sterile factories create miniature medical implants, which are its main material asset. The chart shows the share of this unique ophthalmology manufacturing infrastructure the company controls.
Market segment balance sheet capitalization - Pharma eyes
Glaukos Corporation produces innovative devices for the treatment of glaucoma. Its business requires investment in high-tech production, making it capital-intensive. The chart below illustrates the scale of the entire ophthalmology sector, providing a backdrop for valuing its assets.
Book value of all companies included in the broad market index - GURU.Markets
Glaukos Corporation is a pioneer in microinvasive glaucoma surgery. The company's assets include its manufacturing and R&D capabilities. Its stake in BCap_All provides the necessary resources for the development of miniature implants that are transforming the treatment of one of the most common eye diseases.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Glaukos Corporation
Glaukos is a pioneer in glaucoma microsurgery. Its balance sheet is based on its manufacturing capacity. Its market valuation reflects its belief in its innovative products. Its high P/B is a reward for its intellectual property and its ability to change the standards of ophthalmological treatment.
Market to book capitalization ratio in a market segment - Pharma eyes
Glaukos is an ophthalmology company that develops and manufactures devices for the treatment of glaucoma. Its value is determined by innovative products and patents. The chart shows the premium investors pay for its technological leadership in the niche of microinvasive glaucoma surgery.
Market to book capitalization ratio for the market as a whole
Glaukos Corporation is an ophthalmology company specializing in the development of minimally invasive glaucoma treatments. Compared to average market valuations, as shown in this chart, its high premium reflects the innovativeness of its products, but also the risks associated with competition and changes in the reimbursement system.
Debts of the company, segment and market as a whole
GKOS - Company debts Glaukos Corporation
Glaukos Corporation, a company specializing in the development of technologies for the treatment of glaucoma and other eye diseases, uses debt to finance innovation. The debt burden reflects the high costs of clinical trials, obtaining regulatory approvals, and bringing new minimally invasive surgical devices and pharmaceuticals to market.
Market segment debts - Pharma eyes
Glaukos Corporation is an ophthalmology company specializing in glaucoma treatment. It develops and manufactures innovative medical devices and medications. This chart reflects how the company funds its expensive research and development efforts, striving to offer new treatments to preserve the sight of millions of people worldwide.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Glaukos Corporation
Glaukos Corporation develops and markets innovative glaucoma treatments. Like many companies in the medical technology sector, it invests heavily in R&D and clinical research. This chart illustrates the company's reliance on debt financing to bring its products to market and compete with larger players.
Market segment debt to market segment book capitalization - Pharma eyes
Glaukos Corporation specializes in developing innovative treatments for glaucoma and other eye diseases. This chart shows the overall debt burden in the ophthalmic pharmaceutical and medical device sector. It helps assess how companies finance their expensive research and product launches.
Debt to book value of all companies in the market
Glaukos, a glaucoma treatment device manufacturer, operates in the non-cyclical healthcare sector. This chart shows the overall debt level in the market. It allows one to assess how Glaukos's stable business compares to overall macroeconomic fluctuations and how the company uses its leverage for R&D and acquisitions.
P/E of the company, segment and market as a whole
P/E - Glaukos Corporation
Glaukos Corporation is an ophthalmology company developing innovative treatments for glaucoma and other eye diseases. This chart shows that the company's valuation is based on the potential of its technologies to change treatment standards. Investors are betting on future sales growth for its unique medical devices.
P/E of the market segment - Pharma eyes
Glaukos's focus on developing ophthalmological medical devices is an innovative sector. This chart shows the average valuation for medical device companies. It helps us understand the premium investors are willing to pay for Glaukos's breakthrough glaucoma treatment technologies compared to those of more traditional companies.
P/E of the market as a whole
Glaukos Corporation is an ophthalmology company specializing in the development of glaucoma treatment technologies. Its valuation depends on the success of its innovative products and their adoption by surgeons. General economic cycles, reflected in this chart, have little impact on demand for its products, which is driven by medical needs. For Glaukos, decisions by regulators and insurance companies are more important.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Glaukos Corporation
Glaukos Corporation is an ophthalmology company specializing in the development of technologies for the treatment of glaucoma and other eye diseases. Future profits depend on the adoption of its innovative products by surgeons. This chart shows analysts' estimates of the growth potential of the minimally invasive glaucoma surgery market and the company's new drugs.
%20P%2FE%20Glaukos%20Corporation&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Glaukos-Corporation&v=1772513882833 "Chart of the company's future (projected) P/E Glaukos Corporation")
Future (projected) P/E of the market segment - Pharma eyes
Glaukos Corporation is an ophthalmic technology company and a pioneer in microinvasive glaucoma surgery (MIGS). This chart compares its future profitability expectations with those of the medical technology sector. It helps understand how highly the market values its innovative eye care products and its potential for expansion into new markets.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20eyes&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-eyes&v=1772513882860 "Future (projected) P/E graph of the market segment - Pharma eyes")
Future (projected) P/E of the market as a whole
Glaukos Corporation is an ophthalmology company that develops and manufactures devices for the treatment of glaucoma. This chart shows overall market sentiment. Glaukos's business is driven by demographic trends, such as an aging population and the prevalence of glaucoma. This medical need ensures stable demand, independent of the state of the economy.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513882944 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Glaukos Corporation
Glaukos Corporation is an ophthalmology company specializing in the development and commercialization of innovative treatments for glaucoma, corneal diseases, and retinal diseases. This chart shows the financial trajectory of the company as it introduces new technologies into eye surgery. Profitability depends on the acceptance of its products by physicians and reimbursement by insurance companies.
Profit of companies in the market segment - Pharma eyes
Glaukos Corporation is an ophthalmic technology company pioneering microinvasive glaucoma surgery (MIGS). Its products help reduce intraocular pressure. This chart shows the overall profitability of the ophthalmic device sector, which is growing thanks to an aging population and technological innovation.
Overall market profit
Glaukos Corporation is an ophthalmology company developing treatments for glaucoma and other eye diseases. Demand for its products is driven by the medical needs of an aging population. This makes Glaukos's business non-cyclical and resilient to economic downturns. Patient health, not the economy, is the company's primary driver.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Glaukos Corporation
Glaukos is a medical device company that pioneered microinvasive glaucoma surgery (MIGS), creating new treatments for this disease. Its future depends on the adoption of its technologies by ophthalmologists. This chart reflects analysts' expectations for the growth of this innovative market segment.
%20profit%20of%20the%20company%20Glaukos%20Corporation&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Glaukos-Corporation&v=1772513883110 "Graph of future (projected) profit of the company Glaukos Corporation")
Future (predicted) profit of companies in the market segment - Pharma eyes
Glaukos Corporation is an ophthalmology company focused on developing and commercializing breakthrough technologies for the treatment of glaucoma, corneal diseases, and retina. This chart shows forecasts for the medical technology sector. Glaukos is a pioneer in microinvasive glaucoma surgery (MIGS), creating an entirely new category of treatment.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20eyes&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-eyes&v=1772513883126 "Graph of future (predicted) profits of companies in a market segment - Pharma eyes")
Future (predicted) profit of the market as a whole
Glaukos is a company specializing in the development of innovative treatments for glaucoma and other eye diseases. Demand for its products is primarily driven by medical needs. However, this expected profit curve impacts healthcare system budgets and the willingness of patients and physicians to embrace new, often more expensive, treatment technologies.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513883142 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Glaukos Corporation
Glaukos Corporation is an ophthalmology company that develops and manufactures devices for the treatment of glaucoma. This chart shows how highly investors value its revenue. It reflects their belief in the innovativeness of its products, the growth potential of the eye treatment market, and the success of its new developments.
P/S market segment - Pharma eyes
Glaukos Corporation is an ophthalmology company specializing in the development of innovative treatments for glaucoma, corneal diseases, and retinal diseases. Its revenue depends on the adoption of its technologies by surgeons. This chart reflects the average valuation in the medical technology sector, helping to understand how the market views Glaukos's scientific potential and commercial prospects.
P/S of the market as a whole
Glaukos Corporation is an ophthalmology company developing innovative treatments for glaucoma and other eye diseases. Its revenue depends on the success of its medical devices and drugs. This revenue metric helps understand how highly investors value medical innovation and growth potential in the eye health niche.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Glaukos Corporation
Glaukos Corporation is an ophthalmology company developing innovative treatments for glaucoma and other eye diseases. This chart shows how the market estimates future revenue, which depends on the adoption of its microinvasive surgical devices by physicians and the success of new products in development.
%20P%2FS%20Glaukos%20Corporation&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Glaukos-Corporation&v=1772513883195 "The graph of the company's future (projected) P/S Glaukos Corporation")
Future (projected) P/S of the market segment - Pharma eyes
Glaukos is a company specializing in the development of minimally invasive devices for the treatment of glaucoma. This chart compares the company's future revenue expectations with the medical technology sector, reflecting investors' belief that its innovative products will change the standard of care for this disease.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20eyes&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-eyes&v=1772513883258 "Future (projected) P/S market segment graph - Pharma eyes")
Future (projected) P/S of the market as a whole
Glaukos Corporation is an ophthalmology company focused on developing innovative treatments for glaucoma and other eye diseases. This chart shows overall revenue expectations, and Glaukos is an example of a source of these expectations. The company's breakthrough technologies have the potential to change treatment standards and create new multibillion-dollar markets in ophthalmology.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513883269 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Glaukos Corporation
Glaukos is a company specializing in the development and commercialization of innovative treatments for glaucoma and other eye diseases. Revenue, shown in this chart, is generated from sales of its microinvasive surgical devices that help reduce intraocular pressure.
Sales of companies in the market segment - Pharma eyes
Glaukos Corporation is an ophthalmology company pioneering microinvasive glaucoma surgery (MIGS). Their innovative devices are changing the approach to treating this disease. This chart reflects the growth of the vision technology market, where Glaukos' breakthrough products are creating entirely new treatment standards and market niches.
Overall market sales
Glaukos Corporation is an ophthalmology company developing innovative treatments for glaucoma and other eye diseases. The growth in total revenue, reflected in the graph, impacts healthcare funding. In a favorable economic environment, patients and insurance companies are more willing to accept new, more effective, albeit more expensive, technologies offered by Glaukos.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Glaukos Corporation
Glaukos Corporation is an ophthalmology company focused on the development and commercialization of innovative treatments for glaucoma, corneal diseases, and retinal diseases. Its revenue forecast reflects the speed of adoption of its technologies by surgeons and patients, indicating the company's potential to transform the standard of eye care.
%20sales%20of%20the%20company%20Glaukos%20Corporation&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Glaukos-Corporation&v=1772513883486 "Schedule of future (projected) sales of the company Glaukos Corporation")
Future (projected) sales of companies in the market segment - Pharma eyes
Glaukos Corporation is an ophthalmology company specializing in the development and commercialization of innovative treatments for glaucoma, corneal diseases, and retinal diseases. This chart shows forecasts for the pharmaceutical industry, helping to assess how Glaukos' breakthrough technologies can change the standard of eye care and capture the market.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20eyes&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-eyes&v=1772513883489 "Schedule of future (projected) sales of companies in the market segment - Pharma eyes")
Future (projected) sales of the market as a whole
Glaukos Corporation, a glaucoma treatment specialist, sees this chart as an indicator of the availability of advanced medical technologies. The economic growth reflected here means more patients and clinics can afford the innovative, minimally invasive surgical devices developed and manufactured by Glaukos.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513883490 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Glaukos Corporation
Glaukos Corporation is an ophthalmology company developing innovative treatments for glaucoma and other eye diseases. Profitability depends on the successful commercialization of its unique medical devices and products. This chart shows how sales revenue covers research, development, and marketing costs, turning scientific breakthroughs into financial returns.
Market segment marginality - Pharma eyes
Glaukos Corporation is an ophthalmology technology company specializing in the development and commercialization of innovative devices and medications for the treatment of glaucoma. This chart compares its profitability with other companies in the medical technology sector. Its leadership in microinvasive glaucoma surgery allows the company to maintain high margins on its products.
Market marginality as a whole
Glaukos Corporation is a pioneer in microinvasive glaucoma surgery, developing tiny implants to reduce intraocular pressure. Based on its overall profitability, Glaukos is at the forefront of ophthalmology. Its profitability depends on the adoption of its technologies by surgeons and the demographic trend of an aging population.
Employees in the company, segment and market as a whole
Number of employees in the company Glaukos Corporation
Glaukos Corporation is an ophthalmology company developing innovative glaucoma treatments. This chart shows the growth of its scientific and commercial teams. The increase in staff, particularly in the sales department, is key to promoting its minimally invasive surgical devices to physicians.
Share of the company's employees Glaukos Corporation within the market segment - Pharma eyes
Glaukos Corporation is a pioneer in microinvasive glaucoma surgery (MIGS), developing breakthrough treatments. This chart shows the percentage of all specialists—scientists, engineers, and clinicians—in ophthalmic surgery that Glaukos employs. This reflects its innovative leadership and contribution to changing treatment standards.
Number of employees in the market segment - Pharma eyes
Glaukos Corporation is an ophthalmology company that develops and manufactures devices for the treatment of glaucoma. Its success depends on a team of scientists, engineers, and sales professionals. This chart shows how the company is expanding to commercialize its products. The growth in staff reflects the introduction of new technologies to the market and the training of surgeons.
Number of employees in the market as a whole
Glaukos Corporation develops and markets innovative devices for the treatment of glaucoma. It is a medical technology company whose growth depends on the introduction of new treatment methods. Demand for its products is driven by medical needs, not the state of the economy. Glaukos is an example of a company creating high-tech jobs at the intersection of engineering and medicine.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Glaukos Corporation (GKOS)
Glaukos Corporation develops and manufactures innovative devices for the treatment of glaucoma. It is a high-tech medical business. The high value on this chart reflects the value of intellectual property, patents, and growth potential in the ophthalmology market.
%20of%20the%20company%20Glaukos%20Corporation%20(GKOS)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Glaukos-Corporation-GKOS&v=1772513883586 "Chart of market capitalization per employee (in thousands of dollars) of the company Glaukos Corporation (GKOS)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma eyes
Glaukos Corporation is an ophthalmology company and a pioneer in microinvasive glaucoma surgery (MIGS). They also develop drugs for the treatment of retinal diseases. This chart shows the average capital per employee in the sector. It demonstrates how much the market values their R&D and niche medical devices.
%20by%20market%20segment%20-%20Pharma%20eyes&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-eyes&v=1772513883593 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma eyes")
Market capitalization per employee (in thousands of dollars) for the overall market
Glaukos Corporation is an ophthalmology company that develops and manufactures innovative devices for the treatment of glaucoma. It is a knowledge-intensive business at the intersection of medicine and engineering. The data in the chart demonstrates the company's high market valuation, where intellectual property and patented technologies generate the bulk of its value.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513883598 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Glaukos Corporation (GKOS)
Glaukos Corporation specializes in medical devices for the treatment of glaucoma (MIGS). This is high-tech medicine. This chart shows how effectively the company commercializes its innovative, but expensive, products. The profit per employee here is the result of successful R&D and collaboration with physicians to implement new treatment standards.
%20Chart%20Glaukos%20Corporation%20(GKOS)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Glaukos-Corporation-GKOS&v=1772513883599 "Company Profit Per Employee (in thousands of dollars) Chart Glaukos Corporation (GKOS)")
Profit per employee (in thousands of dollars) in the market segment - Pharma eyes
Glaukos (GKOS) is a medtech company, a pioneer in "micro-invasive" glaucoma surgery (MIGS). This chart shows the benchmark for "Pharma Eyes" (Medtech). In this R&D sector, the benchmark is high (assuming the company is profitable). It's an "R&D business," where profit per employee is generated by "patents" for innovative, high-margin "micro-stents."
%20in%20the%20market%20segment%20-%20Pharma%20eyes&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-eyes&v=1772513883603 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma eyes")
Profit per employee (in thousands of dollars) for the market as a whole
Glaukos (GKOS) is an ophthalmology technology company specializing in the development of minimally invasive glaucoma devices (MIGS). They also develop retinal treatments. This chart, which shows the average profit per employee across the market, helps us understand how the high-tech medical equipment sector, where R&D and engineers create high added value, outperforms the "average" labor efficiency.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513883624 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Glaukos Corporation (GKOS)
Glaukos Corporation is an ophthalmology company developing innovative treatments for glaucoma and other eye diseases. This chart shows how their medical technologies translate into revenue. This growth reflects the growing acceptance of their products by surgeons and the team's ability to effectively bring new solutions to market.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Glaukos-Corporation-GKOS&v=1772513883629 "Sales chart per company employee Glaukos Corporation (GKOS)")
Sales per employee in the market segment - Pharma eyes
Glaukos Corporation is an ophthalmology company, a pioneer in microinvasive glaucoma surgery (MIGS). They are also expanding into retinal treatments. This chart shows the average revenue per employee in the sector. It helps assess how productive Glaukos's commercial and R&D teams are in advancing their innovative medical products.
Sales per employee for the market as a whole
Glaukos Corporation specializes in glaucoma treatment technologies (MIGS – minimally invasive surgery). It's a high-tech medical business. This chart demonstrates how effectively their R&D and sales teams generate revenue. Growth here reflects the successful adoption of their innovative (and expensive) implants into surgical practice.
Short shares by company, segment and market as a whole
Shares shorted by company Glaukos Corporation (GKOS)
Glaukos is a company specializing in the development of minimally invasive devices for the treatment of glaucoma. This is a niche ophthalmology market. The chart shows the number of investors who are skeptical of its products. They may be betting that the new devices will not be widely adopted by surgeons or that insurance companies will refuse to adequately cover them.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Glaukos-Corporation-GKOS&v=1772513883701 "Short Shares Chart for the Company Glaukos Corporation (GKOS)")
Shares shorted by market segment - Pharma eyes
Glaukos is a pioneer in microinvasive glaucoma surgery (MIGS), offering miniature stents for the eye. This chart illustrates the overall pessimism in the sector. It reflects investors' concerns about changes in Medicare reimbursement regulations, which could dramatically reduce the attractiveness of procedures for the entire MIGS niche.
Shares shorted by the overall market
Glaukos (GKOS) produces devices for glaucoma treatment. Many of these procedures are elective. This Short_All chart shows recession fears. When recessionary fears rise, this pessimism leads patients (concerned about their jobs and insurance) to postpone non-urgent surgeries, which directly impacts demand for GKOS devices.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Glaukos Corporation (GKOS)
Glaukos Corporation develops devices for the treatment of glaucoma. Business depends on the adoption of the technology by doctors and the volume of elective surgeries. A chart above 70 may reflect strong demand or the success of new products. A level below 30 may be associated with reimbursement issues or a slowdown in procedures.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Glaukos-Corporation-GKOS&v=1772513883742 "RSI 14 indicator chart for the company's stock Glaukos Corporation (GKOS)")
RSI 14 Market Segment - Pharma eyes
Glaukos Corporation is a pioneer in microinvasive glaucoma surgery (MIGS). They develop and manufacture tiny implants (iStent) that help reduce intraocular pressure. This chart measures the overall momentum in the ophthalmic medical device sector. It helps assess whether this entire niche segment is overheated by innovation.
RSI 14 for the overall market
Glaukos is an ophthalmology company developing innovative treatments for glaucoma and other eye diseases. It's a high-tech company. This chart shows investors' overall risk appetite. In times of panic, investors may sell off growth stocks, even in the medical field, fearing a slowdown in the adoption of new technologies.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast GKOS (Glaukos Corporation)
Glaukos (GKOS) is an ophthalmology company developing innovative treatments for glaucoma, corneal diseases, and retina. This chart shows the average 12-month forecast of analysts. Its dynamics reflect their confidence in the approval and commercial success of the company's new minimally invasive technologies.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-GKOS-Glaukos-Corporation&v=1772513883802 "A chart showing analyst consensus forecasts for the expected stock price. GKOS (Glaukos Corporation)")
The difference between the consensus estimate and the actual stock price GKOS (Glaukos Corporation)
Glaukos is a medical technology company and a pioneer in microinvasive glaucoma surgery (MIGS). It develops miniaturized devices to reduce intraocular pressure. This chart illustrates the analyst community's opinion on the company's future. It measures the distance between the current share price and the consensus target price, demonstrating whether experts believe in their innovations.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-GKOS-Glaukos-Corporation&v=1772513883881 "A chart showing the difference between the consensus forecast and the actual stock price. GKOS (Glaukos Corporation)")
Analyst consensus forecast for stock prices by market segment - Pharma eyes
Glaukos (GKOS) is a MedTech company, a pioneer in microinvasive glaucoma surgery (MIGS). It develops tiny implants to reduce intraocular pressure. This chart shows general expectations for the pharmaceutical sector. It reflects whether experts believe the market for high-tech eye treatments will grow.
Analysts' consensus forecast for the overall market share price
Glaukos (GKOS) is a company specializing in microinvasive devices for glaucoma treatment. This is a highly specialized medical sector. This chart of overall market sentiment is important. Optimism = hospitals and patients are more willing to spend on premium, innovative procedures. During a recession (pessimism), they may prefer cheaper, older methods.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Glaukos Corporation
Glaukos is an ophthalmology company (MedTech) that pioneered the treatment of glaucoma using microinvasive glaucoma devices (MIGS). They are now expanding into other areas, including retinal treatment. This chart evaluates their innovations in eye care. It reflects the rate of adoption of their technologies by surgeons and their ability to obtain approval and reimbursement for new products.
AKIMA Market Segment Index - Pharma eyes
Glaukos (GKOS) is a pioneer in MIGS (Minimally Invasive Glaucoma Surgery); the company produces tiny implants (stents) that help reduce intraocular pressure in glaucoma. This composite metric evaluates companies. The graph shows the sector average. This benchmark: how does Glaukos' innovative technology differentiate it from the average competitor?
The AKIM Index for the overall market
Glaukos is a medtech innovator focused on glaucoma. The company produces micro-stents (MIGS) that help reduce intraocular pressure. This chart, which reflects the market average, provides context. It helps assess how this growth story in the protective healthcare sector compares to the overall macroeconomic trends impacting markets.
